Cash was $14.2 million as of March 31, 2023.Īnebulo Pharmaceuticals, Inc.

Net loss in the third quarter of fiscal 2023 was $2.8 million, or $(0.11) per share, compared with a net loss of $1.9 million, or $(0.08) per share, in the third quarter of fiscal 2022.Operating expenses in the third quarter of fiscal 2023 were $2.9 million compared with $1.9 million in the same period in fiscal 2022.That meeting has now been scheduled for July.'įinancial Results for the three months ended March 31, 2023 We believe these data, in conjunction with our observational study of ACI patients in the emergency room setting, will provide a solid foundation for discussing a registrational path for ANEB-001 with FDA. 'In March, we announced the full positive data from Part B of our Phase 2 study of ANEB-001 in healthy volunteers challenged with THC. 'We are very encouraged by the progress our team has made in developing what has the potential to be the first FDA approved therapy to treat patients suffering from acute cannabinoid intoxication,' said Simon Allen, Chief Executive Officer of Anebulo. Type B meeting with FDA granted for July 2023.Company executives will participate in the BIO International Convention on June 5-8, 2023, in Boston, Massachusetts.Anebulo to host a KOL event in the second quarter CY2023.Anebulo announced positive Phase 2 clinical data demonstrating the potential of ANEB-001 as a treatment for ACI.

Third Q uarter Fiscal Year 2023 and Subsequent Highlights:

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the 'Company' or 'Anebulo'), today announced financial results for the three months ended March 31, 2023, and recent updates. AUSTIN, Texas, /PRNewswire/ - Anebulo Pharmaceuticals, Inc.

Inr antidote